DPRO

Draganfly (DPRO) has completed initial proof-of-concept flights for its medical drone delivery pilot with Mass General Brigham in Boston, targeting healthcare logistics and emergency response applications. The company trades at a valuation discount (1X forward P/S vs. industry 2.10X) but shares have declined 28% in six months, and the stock carries a Zacks Rank #5 (Strong Sell) rating.

Zacks has added three stocks to its Strong Sell list: Accendra Health (ACH), Ardelyx (ARDX), and Draganfly (DPRO). All three companies have experienced significant downward revisions to their earnings estimates over the past 60 days, with ACH seeing a 109.4% downward revision, ARDX a 25% revision, and DPRO a 59.6% revision.

Draganfly Inc. (NASDAQ: DPRO) closed a registered direct offering of 1,869,159 common shares at US$5.35 per share, raising approximately US$10 million in gross proceeds. The company plans to use the net proceeds to accelerate development of advanced strategic capabilities and fund general working capital to meet demand in U.S. and international markets. Jett Capital Advisors and Northland Capital Markets served as joint-lead placement agents.